This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 Tumor Proportion Score.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Mirati Therapeutics, Inc.
Start Date
February 26, 2021
End Date
February 28, 2026
Administered By
Duke Cancer Institute
Awarded By
Mirati Therapeutics, Inc.
Start Date
February 26, 2021
End Date
February 28, 2026